Kenneth Mahaffey

ORLANDO, Florida (Reuters) - An experimental anti-clotting drug from Merck & Co failed to meet the main goal of improving a host of cardiovascular problems in a large study and tripled the risk of bleeding in the brain, researchers said on Sunday.

ORLANDO, Florida (Reuters) - An experimental anti-clotting drug from Merck & Co failed to meet the main goal of improving a host of cardiovascular problems in a large study and tripled the risk of bleeding in the brain, researchers said on Sunday.

J&J blood thinner averts strokes as well as Coumadin does in folks with heart rhythm problem. Millions of people who are struggling with the tough-to-use blood thinner warfarin, sold as Coumadin and other brands, may soon have another alternative.